Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T14:40:36.289Z.
Calculation as of: 2026-10-06T14:40:36.289Z.
Quote observation: 2026-10-06T14:30:29.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: a29a88061d86e64317c53e71c63756e58f7ffa0b55551e6148327154cc786467
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
Market Cap
$19.96M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$18.86M
Price/OCF Ratio
N/A
TTM Avg
126.35
3Y Avg
822.33
5Y Avg
822.33
Market Cap
$18.82M
Price/OCF Ratio
N/A
TTM Avg
3510.40
3Y Avg
3510.40
5Y Avg
3510.40
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Actuate Therapeutics Inc (ACTU) | $19.59M | N/A | N/A | N/A | N/A |
| Estrella Immunopharma, Inc. (ESLA)vs › | $19.96M | N/A | N/A | N/A | N/A |
| Cosmos Health Inc. (COSM)vs › | $19.18M | N/A | 14.35 | 40.20 | 40.20 |
| Neuphoria Therapeutics Inc. (NEUP)vs › | $18.86M | N/A | 126.35 | 822.33 | 822.33 |
| NextCure, Inc. (NXTC)vs › | $18.82M | N/A | 3510.40 | 3510.40 | 3510.40 |
| Modular Medical, Inc. (MODD)vs › | $20.50M | N/A | N/A | N/A | N/A |
| Marker Therapeutics, Inc. (MRKR)vs › | $17.34M | N/A | N/A | N/A | N/A |
| Lipocine Inc. (LPCN)vs › | $17.07M | N/A | N/A | N/A | N/A |
| Aytu BioPharma, Inc. (AYTU)vs › | $21.90M | 6.67 | 13.29 | 7.49 | 7.49 |
| Bionano Genomics, Inc. (BNGO)vs › | $16.64M | N/A | N/A | N/A | N/A |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
